期刊检索

  • 2020年第18卷
  • 2019年第17卷
  • 2018年第16卷
  • 2017年第15卷
  • 2016年第14卷
  • 2015年第13卷
  • 2014年第12卷
  • 2013年第11卷
  • 第1期
  • 第2期

主管单位 工业和信息化部 主办单位 哈尔滨工业大学 主编 任南琪 国际刊号ISSN 1672-5565 国内刊号CN 23-1513/Q

期刊网站二维码
微信公众号二维码
引用本文:赵诗哲,徐佳宝,毛金校.SHCBP1:乳腺癌治疗候选靶点和潜在预后标志物[J].生物信息学,2020,18(1):45-55.
ZHAO Shizhe,XU Jiabao,MAO Jinxiao.SHCBP1: A breast cancer treatment target candidate and potential prognostic marker[J].Chinese Journal of Bioinformatics,2020,18(1):45-55.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  下载PDF阅读器  关闭
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 242次   下载 642 本文二维码信息
码上扫一扫!
分享到: 微信 更多
SHCBP1:乳腺癌治疗候选靶点和潜在预后标志物
赵诗哲2,徐佳宝2,毛金校1
(1.重庆医科大学 附属儿童医院药学部;儿童发育疾病研究教育部重点实验室;国家儿童健康与疾病临床医学研究中心;儿童发育重大疾病国家国际科技合作基地;儿科学重庆市重点实验室,重庆市 400010;2.河南大学 基础医学院病理学教研室,河南 开封 475004)
摘要:
探讨SHCBP1在乳腺癌及其不同亚型中的表达特征和预后价值。利用Oncomine, bc-GenExMiner v4.2, Kaplan-Meier plotter, GSE41994及STRING数据库分析乳腺癌病人SHCBP1的mRNA表达水平及其与乳腺癌患者生存率的相关性等。结果:(1)乳腺癌组织中SHCBP1的mRNA水平明显高于正常组织样本,但不同分子亚型的乳腺癌患者中SHCBP1的表达水平不同;(2) SHCBP1表达升高可导致Luminal A亚型更短的无转移生存期(Distant metastasis-free survival,DMFS)和无病生存期(Disease-free survival, DFS);(3)在雌激素受体阳性(ER+)、孕酮受体阳性(PR+)亚型、仅接受辅助化疗、仅接受辅助化疗的ER(+)与接受包括或排除内分泌治疗乳腺癌患者中,SHCBP1表达升高则无复发生存率(Relapse-free survival,RFS)显著缩短;(4) SHCBP1和CDC45 mRNA表达水平之间呈正相关,并可能与KIF23等10种蛋白相互作用。结论:SHCBP1是一种很有前景的乳腺癌预后指标和潜在的治疗靶点。
关键词:  SHCBP1  乳腺癌  表达水平  预后价值
DOI:10.12113/201909004
分类号:R737.9
文献标识码:A
基金项目:
SHCBP1: A breast cancer treatment target candidate and potential prognostic marker
ZHAO Shizhe2, XU Jiabao2, MAO Jinxiao1
(1. Department of Pharmacy, Childrens Hospital of Chongqing Medical University; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing 400010, China; 2. Department of Pathology, Basic Medical College, Henan University, Kaifeng 475004, Henan, China)
Abstract:
To investigate the expression characteristics and prognostic value of SHCBP1in breast cancer and its relevant subtypes, the Oncomine, bc-GenExMiner v4.2, Kaplan-Meier plotter, GSE41994, and STRING databases were used to analyze the mRNA expression level of SHCBP1in breast cancer patients and its correlation with their survival rate. Results show that: (1) The mRNA level of SHCBP1in breast cancer tissues was significantly higher than that of normal tissue samples, but the expression level of SHCBP1in breast cancer patients with different molecular subtypes was different; (2) Increased expression of SHCBP1might lead to shorter distant metastasis-free survival (DMFS) and disease-free survival (DFS) of Luminal A subtype; (3) In patients with ER(+), PR(+) subtype, chemo-adjuvant only, ER(+) with chemo-adjuvant therapy, endocrine therapy-include, and endocrine therapy-exclude breast cancer, elevated SHCBP1expression significantly correlated with shorten relapse-free survival rate (RFS); (4) SHCBP1and CDC45 mRNA expression levels were positively correlated and SHCBP1might interact with 10 proteins such as KIF23. Therefore, SHCBP1may be a promising prognostic indicator and therapeutic target for breast cancer.
Key words:  SHCBP1  Breast cancer  Expression level  Prognostic value.

友情链接LINKS

关闭